



HAL
open science

Rapid Efficacy of anifrolumab in refractory cutaneous lupus erythematosus: a prospective study of 11 patients with systemic lupus erythematosus

François Chasset, Léa Jaume, Alexis Mathian, Noémie Abisoror, Amélie Dutheil, Annick Barbaud, Diane Kottler, Céline Girard, Sandrine Jousse-Joulin, Marie Tauber, et al.

► To cite this version:

François Chasset, Léa Jaume, Alexis Mathian, Noémie Abisoror, Amélie Dutheil, et al.. Rapid Efficacy of anifrolumab in refractory cutaneous lupus erythematosus: a prospective study of 11 patients with systemic lupus erythematosus. *Journal of The American Academy of Dermatology*, 2023, 89 (1), pp.171-173. 10.1016/j.jaad.2023.02.044 . hal-04145029

HAL Id: hal-04145029

<https://hal.sorbonne-universite.fr/hal-04145029>

Submitted on 29 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

Rapid Efficacy of anifrolumab in refractory cutaneous lupus erythematosus: a prospective study of 11 patients with systemic lupus erythematosus

François Chasset, MD, PhD^{1*}, Léa Jaume, MD^{1*}, Alexis Mathian², MD, PhD, Noémie Abisror, MD³, Amélie Dutheil, MD¹, Annick Barbaud, MD, PhD¹, Diane Kottler, MD⁴, Céline Girard MD⁵, Sandrine Jousse-Joulin, MD⁶, Marie Tauber, MD⁷, Cristina Bulai Livideanu, MD^{7,8}, Véronique Avettand-fenoel, MD, PhD⁹, Raphael Lhote, MD², Micheline Pha, MD², Zahir Amoura, MD, MSc², for the EMSED (Etude des maladies systémiques en dermatologie) study group.

¹ Sorbonne Université, Faculté de médecine, AP-HP, Service de Dermatologie et Allergologie, Hôpital Tenon, INSERM U-1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris) Paris, France

² Sorbonne université, Faculté de médecine, AP-HP, Groupement Hospitalier Pitié-Salpêtrière, Centre national de référence du lupus systémique, du syndrome des antiphospholipides et autres maladies auto-immunes, Service de Médecine Interne 2, Institut E3M, CIMI-Paris, Paris, France

³ Sorbonne Université, Faculté de médecine, AP-HP, Service de Medecine Interne, Hôpital Saint-Antoine, Paris, France

⁴ Service de dermatologie et vénérologie, CHU de Caen, Caen, France

⁵ Service de dermatologie et vénérologie, CHU de Montpellier, Montpellier, France

⁶ Service de rhumatologie, CHU de Brest, Université de Brest, Inserm, LBAI, UMR1227, Brest, France

⁷ Service de dermatologie, CHU de Toulouse, Université Paul Sabatier Toulouse III, Toulouse, France

⁸ Infinity, Institut Toulousain des maladies infectieuses et inflammatoires, CNRS, Université Paul Sabatier Toulouse III, Inserm, Toulouse, France.

⁹ Université Paris Cité, Faculté de médecine, Institut Cochin - CNRS 8104 / INSERM U1016 AP-HP, Service de Virologie, Hôpital Cochin, Paris, France

* Contributed equally and shared the first authorship

Corresponding author:

François Chasset, MD, PhD

AP-HP, Service de Dermatologie et d'Allergologie, Sorbonne Université, Hôpital Tenon

4 Rue de la Chine 75970 Paris CEDEX 20, France

Email: francois.chasset@aphp.fr

Funding sources: None

Consent: all patients gave consent for their medical information to be published in print and online, with the understanding that this information may be publicly available.

Conflict of interest: François Chasset received grant/research support from AstraZeneca, participated in an advisory board related to lupus for AstraZeneca, GSK, Celgene, and Principabio, and received speaking fees and honoraria from AstraZeneca and GSK. Alexis

Mathian has received grant/research support from Sobi; participated in advisory board related to lupus for AstraZeneca; received payment for expert testimony for GSK; received support for attending meetings and/or travel from AstraZeneca and GSK; received consulting fees, speaking fees and honoraria from AstraZeneca, GSK, Otsuka and Novartis. Cristina Bulai Livideanu received speaking fee and honoraria from BluePrint Medicine, Lilly, and UCB and participated in advisory board for Abbvie, Boeringer-Ingelheim, Blueprint Medicine, and UCB. Véronique Avettand-Fenoel received grant/research support and speaking fees from Gilead and ViiV Healthcare. Zahir Amoura has received grant/research support from GSK, AstraZeneca, Roche, Novartis, Amgen; participated in advisory board related to lupus for GSK, AstraZeneca, Kezar, Amgen, Otsuka; received consulting fees, speaking fees and honoraria from AstraZeneca and GSK. The other authors have no conflict of interest to declare. IRB approval status: CEEI/IRB 22-946

Statement of any prior presentation: none

Manuscript word count: 498 words, References: 5, Figures: 1, Tables: 1, Supplementary Figures: 2, Supplementary Table: 1, Supplementary method: 1

Key words: cutaneous lupus erythematosus; systemic lupus erythematosus; refractory; anifrolumab; belimumab

Dear Editor,

Anifrolumab, a human monoclonal antibody that binds IFN-I receptor subunit 11, has been approved for the treatment of systemic lupus erythematosus (SLE). Clinical trials have shown that anifrolumab is effective in cutaneous lupus erythematosus (CLE) associated with SLE 1,2. A few case reports have suggested the efficacy of anifrolumab in refractory CLE 3. However, its real-life efficacy in the setting of CLE refractory to standard therapies including thalidomide, lenalidomide and belimumab has not been assessed using validated disease activity instruments 4. This national multicenter prospective study enrolled SLE patients with biopsy-proven active CLE despite optimal treatment with failure of at least three currently available CLE treatments, including belimumab (mandatory to be eligible in the early access program in France). Of note, all patients had to be fully vaccinated against COVID-19 before starting anifrolumab. Anifrolumab (300 mg intravenously every 4 weeks) was started between August 2021 and May 2022, and the patients were followed up for a minimum of 16 weeks. The primary outcome was the proportion of partial response (PR) at week 16 defined by a decrease of CLE Disease Area and Severity Index activity of at least 50% (CLASI-A 50)1,4. SLE activity (SELENASLEDAI score5) and adverse events were also assessed (Supplementary Methods). Analyses were performed using the JMP 15 software (SAS

Institute, Cary, NC, USA). The study protocol was approved by our local IRB (CEEI/IRB 22-946). Eleven women were included in the study. The detailed characteristics at baseline are presented in Table 1. Before starting anifrolumab, the median number of systemic treatment lines for CLE per patient was 6 (3-9). CLASI-A 50 at week 16 was reached by the 11 patients. The median CLASI activity decreased from 15 (4-35) at baseline to 4 (0-19) at week 4 ($p=0.001$) and 2 (0-13) at week 16 ($p<0.001$) (*Figure 1*). The median time to reach CLASI-A 50 was one month (95% CI 1-3) (*Supplementary Figure 1*). Seven patients received additional infusions after week 16, up to week 40 for one patient. All patients showed sustained improvement in CLASI activity. A complete response (CLASI-A=0) was observed in 6 patients (54%). No significant variation in the median CLASI damage was observed (*Supplementary Figure 2*). The median SELENA-SLEDAI score significantly decreased from 8 (4-22) at baseline to 4 (0-10) at week 16 ($p=0.002$) (*Supplementary Figure 2*), and all 5 patients with baseline articular involvement had disappearance of their clinical symptoms. The median dose of prednisone decreased from 10 mg/day (0-15) to 5 mg/day (0-10). Eight (73%) patients had at least one AEs, with a total of 10 AEs (*Supplementary Table 1*). No patient discontinued anifrolumab permanently because of an AE. Infectious AEs included two non-severe COVID-19 cases with spontaneous recovery (grade 1) (for which anifrolumab infusion was delayed for 2 weeks), one herpes zoster, one case of worsening preexisting palmar warts, and one case of mucosal candidiasis. The main limitations of this study are its limited sample size and follow-up duration. Overall, anifrolumab is a promising therapeutic option for refractory CLE.

References

1. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N Engl J Med*. 2020;382(3):211-221. doi:10.1056/NEJMoa1912196
2. Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. *Lancet Rheumatol*. 2019;1(4):e208-e219. doi:10.1016/S2665-9913(19)30076-1
3. Blum FR, Sampath AJ, Foulke GT. Anifrolumab for treatment of refractory cutaneous lupus erythematosus. *Clin Exp Dermatol*. 2022;47(11):1998-2001. doi:10.1111/ced.15335
4. The CLASI (Cutaneous LE Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus. *J Am Acad Dermatol*. 2005;52(3):AB6. doi:10.1016/j.jaad.2005.01.045
5. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med*. 2005;353(24):2550-2558. doi:10.1056/NEJMoa051135




Figure 1 legend : CLASI activity in 11 patients before and at weeks 4, 8, 12, and 16 of anifrolumab treatment. Black solid circles represent individuals. The red bar indicates the median values calculated only between weeks 0 and 16. P-values were calculated using the Mann-Whitney U test. $p < 0.05$ was considered significant. W, week. Anifrolumab exposure after week 16 is also reported. CLE subtypes of patients achieving complete response were both subacute and localized DLE $n=3$, subacute and chilblain lupus $n=1$, localized DLE $n=1$ and disseminated DLE $n=1$

Table 1: Patient characteristics and disease parameters SLE patients (n = 11)

<i>Socio-demographic features</i>	
Age at baseline, median (range)	35 (19-50)
<u>Phototype:</u>	
- I-IV	7 (64)
- V-VI	4 (36)
Female sex	11 (100)
Active smoking at last follow-up	4 (36)
SLE duration, years, median (range)	12 (3-23)
<i>Historical treatment and belimumab history</i>	
- Hydroxychloroquine	11 (100)
- Chloroquine	1 (9)
- Glucocorticoids	10 (91)
- Methotrexate	8 (73)
- Thalidomide or lenalidomide	11 (100)
- Other immunosuppressant or immunomodulatory drug*	8 (73)
<i>Previously treated with Belimumab</i>	11(100)
Median duration of belimumab (month), median (range)	24 (2-72)
<u>Belimumab efficacy:</u>	
- Partial response and secondary relapse	5 (45)
- Primary failure	6 (55)
<i>Median number of systemics before starting anifrolumab, median (range)</i>	6 (3-7)
<i>Active CLE features at the time of anifrolumab initiation</i>	
<u>Active cutaneous subtypes at baseline:</u>	
- Discoid CLE	10 (91)
- Subacute CLE	4 (36)
- Chilblains lupus	1 (9)
- More than one subtype**	4 (36)
<u>Specific topography of CLE</u>	
- Scalp discoid lupus	6 (54)
- Digital involvement	7 (64)
- Mucosal involvement	6 (54)
<i>Treatments continued with anifrolumab</i>	
Hydroxychloroquine	10 (91)
Chloroquine	1 (9)
Systemic glucocorticoids	9 (82)
Systemic glucocorticoids dose (mg), median (range)	10 (2-15)
Methotrexate	2 (18)
Mycophenolate mofetil	2 (18)
Thalidomide or lenalidomide	2 (18)
<i>Baseline CLE and SLE activity and damage at the time of anifrolumab initiation</i>	
CLASI activity at baseline, median (range)*	15 (4-35)
CLASI damage at baseline, median (range)*	6 (0-25)
SLEDAI at baseline, median (range)**	8 (4-22)

Values are expressed as n (%) unless stated otherwise. *Mycophenolate mofetil (n=4), Azathioprine (n=4), Cyclophosphamide (n=1), Rituximab (n=3) ** All patients with subacute lupus had another CLE subtype including discoid lupus (n=3) and chilblain lupus (n=1)" CLASI: CLE Disease Area and Severity Index, SLEDAI: Systemic Lupus Erythematosus Disease Activity Index